Overview

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Marc L Gordon, MD
Collaborator:
Janssen Scientific Affairs, LLC
Treatments:
Antibodies, Monoclonal
Daratumumab